Literature DB >> 19357829

Technophobia, prescription checking and the future of diabetes management.

A M Albisser1.   

Abstract

Is the medical prescription the root cause of the long-term complications of diabetes mellitus? This article presents the argument for introducing prescription checking into diabetes disease management. It discusses an evidence-based need for frequent revisions of the medical prescription as the key to preventing treatment-related complications in diabetes while achieving the now mandated standards in patient care. To do this it will be prudent for diabetes healthcare providers to enrich their clinical services with new information technology-based tools. These are easily acquired by participating in professional workshops focused on advanced diabetes management. In this light, the case presented here challenges leading practitioners to become early participants in the evolution of information technology that will ultimately enhance the management of all patients with diabetes.

Entities:  

Mesh:

Year:  2009        PMID: 19357829     DOI: 10.1007/s00125-009-1341-8

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  9 in total

Review 1.  Clinical inertia.

Authors:  L S Phillips; W T Branch; C B Cook; J P Doyle; I M El-Kebbi; D L Gallina; C D Miller; D C Ziemer; C S Barnes
Journal:  Ann Intern Med       Date:  2001-11-06       Impact factor: 25.391

2.  Closing the circle of care with new firmware for diabetes: MyDiaBase+RxChecker.

Authors:  A Michael Albisser; Rodolfo Alejandro; Marianne Sperlich; Camillo Ricordi
Journal:  J Diabetes Sci Technol       Date:  2009-05-01

3.  Prescription checking device promises to resolve intractable hypoglycemia.

Authors:  A Michael Albisser; Rodolfo Alejandro; Marianne Sperlich; Camillo Ricordi
Journal:  J Diabetes Sci Technol       Date:  2009-05-01

4.  Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort.

Authors: 
Journal:  Diabetes Care       Date:  1999-01       Impact factor: 19.112

5.  Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group.

Authors: 
Journal:  Am J Med       Date:  1991-04       Impact factor: 4.965

Review 6.  Hypoglycemia: still the limiting factor in the glycemic management of diabetes.

Authors:  Philip E Cryer
Journal:  Endocr Pract       Date:  2008-09       Impact factor: 3.443

7.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

8.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

9.  Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial--revisited.

Authors:  John M Lachin; Saul Genuth; David M Nathan; Bernard Zinman; Brandy N Rutledge
Journal:  Diabetes       Date:  2008-01-25       Impact factor: 9.461

  9 in total
  2 in total

Review 1.  Smart telemedicine support for continuous glucose monitoring: the embryo of a future global agent for diabetes care.

Authors:  Mercedes Rigla
Journal:  J Diabetes Sci Technol       Date:  2011-01-01

2.  How to translate therapeutic recommendations in clinical practice guidelines into rules for critiquing physician prescriptions? Methods and application to five guidelines.

Authors:  Jean-Baptiste Lamy; Vahid Ebrahiminia; Christine Riou; Brigitte Seroussi; Jacques Bouaud; Christian Simon; Stéphane Dubois; Antoine Butti; Gérard Simon; Madeleine Favre; Hector Falcoff; Alain Venot
Journal:  BMC Med Inform Decis Mak       Date:  2010-05-28       Impact factor: 2.796

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.